Barettin Suppresses Pancreatic Ductal Adenocarcinoma Proliferation via Topoisomerase IIα Inhibition
Marine Drugs · 07.06.2026 · 24 (6) · 201
DOI: 10.3390/md24060201 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, online erschienen am 07.06.2026. Verfasst von Caleb A Seekins und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85724, USA. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Topoisomerase II Inhibitors, Pancreatic Neoplasms, Diketopiperazines. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Arizona Biomedical Research Commission, American Cancer Society, American Society of Pharmacognosy.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy with few therapeutic options. Topoisomerase IIα (TOPO2α) is frequently overexpressed in PDAC and is associated with poor clinical outcomes, yet current TOPO2α-directed therapies are constrained by limited efficacy and toxicity. Barettin, a brominated indole-containing diketopiperazine isolated from the marine sponge Geodia barretti, has not previously been evaluated against PDAC-relevant targets. Here, we identify barettin as a TOPO2α inhibitor using an integrated phenotypic, computational, and biochemical approach. Barettin exerts a cytostatic, non-toxic effect, selectively suppressing proliferation in a subset of PDAC models while showing reduced activity in others, revealing context-dependent efficacy and biological selectivity. Consistent with this, barettin inhibits TOPO2α-mediated DNA decatenation in vitro, demonstrating direct interference with enzyme activity. These findings support barettin as a selective inhibitor of a cancer-relevant proliferative pathway, uncovering a potential vulnerability in a subset of PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85724, USA.
- Department of Chemistry and Biochemistry, College of Science, University of Arizona, Tucson, AZ 85724, USA.
- Department of Pharmacology & Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ 85724, USA.
- Comprehensive Center for Pain and Addiction, University of Arizona, Tucson, AZ 85724, USA.
- Pharmacognosy, Department of Medicinal Chemistry, Uppsala University, 752 37 Uppsala, Sweden.
- Museum of Evolution, Uppsala University, 752 37 Uppsala, Sweden.
ORCID-Profile: Caleb A Seekins, Jerry E Carr, Vishal Kaleeswaran, Kayla B Nguyen, Paco Cárdenas, Nam Y Lee, Christopher Cartmell
Förderung
- Arizona Biomedical Research Commission
- American Cancer Society
- American Society of Pharmacognosy
Zitieren
APA
Seekins, C. A., Archuleta, M. R., Evans, A. E., Podgorski, J., Carr, J. E., Kaleeswaran, V., Nguyen, K. B., Flowers, M. E., Hulme, C., Vanderah, T. W., Cárdenas, P., Streicher, J. M., Lee, N. Y., & Cartmell, C. (2026). Barettin Suppresses Pancreatic Ductal Adenocarcinoma Proliferation via Topoisomerase IIα Inhibition. Marine Drugs, 24(6), 201. https://doi.org/10.3390/md24060201
Vancouver
Seekins CA, Archuleta MR, Evans AE, Podgorski J, Carr JE, Kaleeswaran V, et al. Barettin Suppresses Pancreatic Ductal Adenocarcinoma Proliferation via Topoisomerase IIα Inhibition. Marine Drugs. 2026;24(6):201. doi:10.3390/md24060201
BibTeX
@article{Seekins2026,
author = {Seekins, Caleb A and Archuleta, Monique R and Evans, Alexandria E and Podgorski, Julia and Carr, Jerry E and Kaleeswaran, Vishal and Nguyen, Kayla B and Flowers, Matthew E and Hulme, Christopher and Vanderah, Todd W and Cárdenas, Paco and Streicher, John M and Lee, Nam Y and Cartmell, Christopher},
title = {Barettin Suppresses Pancreatic Ductal Adenocarcinoma Proliferation via Topoisomerase IIα Inhibition},
journal = {Marine Drugs},
year = {2026},
volume = {24},
number = {6},
pages = {201},
doi = {10.3390/md24060201}
}
EUVIMED